HCC - Alcohol versus other etioloiges

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, can develop due to various etiologies. Alcohol-related liver disease (ALD) is a significant contributor to HCC, alongside other causes such as viral hepatitis (Hepatitis B Virus [HBV] and Hepatitis C Virus [HCV]) and metabolic dysfunction-associated steatotic liver disease (MASLD). Below is a detailed comparison of alcohol-related HCC versus HCC due to other etiologies:

---

### **Alcohol-related Liver Disease (ALD) and HCC**

1. **Definition of ALD:**

ALD refers to liver damage caused by excessive alcohol consumption, which can progress to cirrhosis (advanced scarring of the liver) and eventually lead to HCC. Chronic alcohol use leads to oxidative stress, inflammation, and lipid metabolism dysregulation, which are key contributors to carcinogenesis.

2. **Epidemiological Role:**

• ALD is the **third leading cause** of HCC globally and the **leading cause in Europe**, accounting for approximately **19% of liver cancer deaths**.
• Central and Eastern Europe have the highest mortality rates from ALD-related HCC due to socioeconomic factors and high alcohol consumption rates.

3. **Delayed Diagnosis:**

• HCC in ALD patients is often diagnosed **late or incidentally**, primarily due to the lack of structured surveillance programs and socioeconomic barriers.
• Many patients with ALD-related cirrhosis are underdiagnosed, and active alcohol use often prevents regular medical follow-ups.

4. **Clinical Presentation:**

• ALD-HCC patients frequently present with **poorer general health**, **impaired liver function**, and **comorbidities** such as cardiovascular disease and malnutrition.
• This results in worse clinical outcomes compared to other HCC etiologies.

5. **Molecular Characteristics:**

• ALD-HCC is associated with specific **genetic polymorphisms** such as PNPLA3, TM6SF2, HSD17B13, and MBOAT7, which influence lipid metabolism and carcinogenesis.
• Somatic mutations affecting the **TERT promoter**, **CTNNB1 (β-catenin)**, **TP53**, and **ARID1A** drive tumor progression through mechanisms like oxidative stress, chromatin remodeling, and Wnt/β-catenin pathway activation.

6. **Surveillance and Screening Challenges:**

• ALD patients face significant barriers to HCC surveillance, including cost, transportation issues, stigma, and poor scheduling. Active alcohol use correlates with reduced surveillance orders from healthcare providers.
• Standard ultrasound-based screening is less sensitive in ALD patients due to obesity, fibrosis heterogeneity, and technical limitations, necessitating enhanced imaging methods or biomarker-based approaches.

7. **Treatment Inequalities:**

• Historically, ALD-HCC patients faced stigma and reduced access to curative therapies like liver transplantation. While attitudes are improving, disparities in access to treatment persist internationally.

8. **Prognostic Factors:**

• The etiology of cirrhosis (alcoholic vs. viral) does not independently determine prognosis. Instead, survival depends on liver function, tumor burden, and overall health.
• Early detection through surveillance can improve survival outcomes, making them comparable to virus-related HCC.

---

### **Non-Alcoholic Etiologies of HCC**

1. **Viral Hepatitis (HBV and HCV):**

• HBV and HCV are major global causes of HCC, especially in Asia and Africa.
• Chronic viral hepatitis leads to liver inflammation, fibrosis, and cirrhosis, which increase the risk of HCC.
• HCV-related HCC has slightly higher cumulative incidence rates compared to ALD (e.g., 1% at 1 year, 3-5% at 5 years, and 10-15% at 10 years in cirrhosis patients).

2. **Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD):**

• Formerly known as non-alcoholic fatty liver disease (NAFLD), MASLD is caused by metabolic risk factors such as obesity, diabetes, and dyslipidemia.
• MASLD-related HCC can occur even in the absence of cirrhosis, making surveillance crucial.
• A new classification, **Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake (MetALD)**, identifies patients with moderate alcohol use and metabolic risk factors who have distinct HCC risk profiles.

3. **Cumulative Incidence Rates:**

• MASLD-related cirrhosis has slightly higher HCC incidence rates compared to ALD-related cirrhosis (e.g., 2% at 1 year, 5% at 5 years, and 13% at 10 years).

4. **Molecular Pathways:**

• Viral hepatitis HCC is often driven by viral integration into the host genome, inflammation, and activation of oncogenic pathways.
• MASLD-HCC involves metabolic dysfunction, lipid accumulation, and insulin resistance, contributing to tumorigenesis.

5. **Surveillance and Prognosis:**

• Structured surveillance programs improve early-stage detection and survival outcomes for both viral and MASLD-related HCC.
• MASLD patients often face barriers to surveillance due to underdiagnosis of liver disease in non-cirrhotic stages.

---

### **Alcohol versus Non-Alcohol Etiologies: Key Differences**

| **Aspect** | **Alcohol-Related HCC (ALD)** | **Non-Alcohol-Related HCC (Viral/MASLD)** |

|-------------------------------|--------------------------------------------------|------------------------------------------------|

| **Primary Cause** | Excessive alcohol consumption | Chronic viral hepatitis, obesity, diabetes |

| **Global Impact** | Third leading cause of HCC globally | HBV is dominant in Asia/Africa; MASLD rising |

| **Risk Factors** | Alcohol abuse, socioeconomic deprivation | Viral infection, metabolic syndrome |

| **Surveillance Challenges** | Poor access, stigma, active alcohol use | Underdiagnosis in non-cirrhotic MASLD |

| **Prognosis** | Worse outcomes due to comorbidities | Better outcomes with early detection |

| **Molecular Pathways** | Lipid metabolism genes (PNPLA3, TM6SF2, etc.) | Viral integration (HBV), metabolic dysfunction |

| **Treatment Access** | Historically limited due to stigma | Better access, though disparities exist |

---

### **Public Health Implications**

• **Alcohol-related HCC** is largely preventable through public health measures aimed at reducing alcohol consumption. Modeling predicts that reducing alcohol use by **3.5% annually** could cut ALD-HCC incidence by **30%** by 2040.
• Enhanced surveillance programs, improved access to care, and integration of molecular diagnostics are essential for reducing mortality across all HCC etiologies.

In conclusion, while alcohol-related HCC presents unique challenges such as delayed diagnosis, socioeconomic barriers, and molecular differences, structured surveillance and prevention strategies can significantly improve outcomes and reduce its global burden.